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Abstract
Objective To estimate the high risk group for cardiovascular
disease in a well defined Norwegian population according to
European guidelines and the systematic coronary risk
evaluation system.
Design Modelling study.
Setting Nord-Tröndelag health study 1995-7 (HUNT 2),
Norway.
Participants 5548 participants of the Nord-Tröndelag health
study 1995-7, aged 40, 50, 55, 60, and 65.
Main outcome measures Distribution of risk categories for
cardiovascular disease, with emphasis on the high risk group.
Main results At age 40, 22.5% (95% confidence interval 19.3%
to 25.7%) of women and 85.9% (83.2% to 88.6%) of men were
at high risk of cardiovascular disease. Corresponding numbers
at age 50 were 39.5% (35.9% to 43.1%) and 88.7% (86.3% to
91.0%) and at age 65 were 84.0% (80.6% to 87.4%) and 91.6%
(88.6% to 94.1%). At age 40, one out of 10 women and no men
would be classified at low risk for cardiovascular disease.
Conclusion Implementation of the 2003 European guidelines
on prevention of cardiovascular disease in clinical practice
would classify most adult Norwegians at high risk for fatal
cardiovascular disease.
Introduction
Mortality from cardiovascular disease has declined considerably
in most European countries since the early 1970s.1 Interventions
to modify risk factors have long been shown to reduce mortality
and morbidity from cardiovascular disease, in both people with
previously unrecognised disease2 and people with established
disease.3 Intervention in people at high risk is an accepted
method for disease prevention. Since the first US Framingham
model for predicting heart disease risk was published in 1991, it
has become ever more widely recommended that doctors in pri-
mary care carry out risk assessment by combining several risk
factors for cardiovascular disease using algorithms. Until recently
most risk equations have been derived from the Framingham
study, but these calculations tended to overestimate risk in the
European context.4 A new European risk scoring system for car-
diovascular disease, based on the first phase of the systematic
coronary risk evaluation (SCORE) project, was presented in
2003.5 The system is based on a pooled dataset of cohort studies
from 12 European countries, among these Norway, and offers a
format for estimating fatal cardiovascular disease risk that is suit-
able for clinical practice.5 The system is embedded in the current
version of the European guidelines on prevention of
cardiovascular disease, issued by the Third Joint Task Force of
European and other Societies on Cardiovascular Disease
Prevention in Clinical Practice in 2003.6 The authoring body
consists of eight European and international medical societies
and experts. The guidelines aim to present all relevant evidence
to facilitate clinical decision making in the primary and second-
ary prevention of cardiovascular disease, which can be adapted
to different political, economic, social, and medical circum-
stances.6
The legal status of clinical guidelines for the prevention of
disease is not fully established,6 but authoritative recommenda-
tions contribute to expert and opinion leaders’ definition of what
constitutes good medical practice. Several studies have, however,
shown clinicians’ limited adherence to medical guidelines for
asymptomatic conditions.6–9 This is the case even in high risk
situations, such as patients with angina pectoris or diabetes mel-
litus.8 This phenomenon, termed “clinical inertia,” has been
partly attributed to too much work, too little time, and “soft rea-
sons to avoid intensification of therapy.”7
Population based data on risk factors for cardiovascular dis-
ease are available for many European regions.10 The 2003 Euro-
pean guidelines, however, provide no estimates of the aggregated
workload associated with implementation of the recommenda-
tions. We recently showed that implementation would result in
three out of four Norwegians aged 20 or older being classed as in
need of counselling because of high cholesterol or blood
pressure levels.11
We estimated the high risk group in the Norwegian popula-
tion participating in the Nord-Tröndelag health study 1995-7
(HUNT 2),12 according to the 2003 European guidelines on pre-
vention of cardiovascular disease.
Materials and methods
The 2003 European guidelines tackle the prevention of athero-
sclerotic disease in general (coronary heart disease, peripheral
artery disease, and cerebrovascular atherosclerotic disease). Risk
is defined in terms of the absolute probability of developing a
fatal cardiovascular event within 10 years, and the threshold for
high risk is defined as ≥ 5%.6 The guidelines 6 specify a list of bio-
medical conditions that classify people at high risk (see box).
These people require maximal clinical attention, with no further
estimation of risk.6 In remaining asymptomatic, apparently
healthy people, risk estimation and counselling should be guided
by the total risk level, as estimated from a chart produced by the
systematic coronary risk evaluation project.
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The chart comprises a table of the parameters sex, smoking
status, systolic blood pressure, total cholesterol (or ratio of total
cholesterol to high density lipoprotein), and age (40, 50, 55, 60,
and 65 years). Risk is estimated by rounding a person’s age to the
nearest one shown on the chart, their cholesterol level to the
nearest whole unit, and their blood pressure to the nearest mul-
tiple of 20 mm Hg.5 The guidelines specifically recommend
extrapolation of the risk estimate to 60 years when counselling
people in the younger age groups.We calculated risk distribution
both with and without extrapolation to evaluate its effect on the
high risk group.
The chart is designed in two versions, for use in high or low
risk populations. As the guidelines state that Norway is a high
risk region, we analysed data using the high risk chart.
The guidelines encourage people with increased risk for car-
diovascular disease to change their lifestyle.6 To facilitate
communication of risk, a person’s combined risk estimate is visu-
alised by “traffic light” colours. High risk is illustrated by increas-
ingly dark shades of red. Intermediate risk (2%-4% risk of a fatal
event within 10 years) is illustrated by yellow-orange, and low risk
( ≤ 1%) by green.
The Nord-Tröndelag health study 1995-7
Our population data were derived from the Nord-Tröndelag
health study 1995-7, a large Norwegian population study that
was designed to investigate the importance of biomedical risk
factors. Its design and methods are described elsewhere.12 Data
were obtained from 66 140 participants. The study population
has been considered fairly representative of the Norwegian
population for demography, socioeconomic factors, morbidity,
and mortality.12
To apply the guidelines’ recommendations as precisely as
possible, we included in the present analysis only people of the
ages shown in the chart. The analysis is based on participants
from the Nord-Tröndelag health study aged 40, 50, 55, 60, and
65 years, totalling 5548 people (2841 women, 2707 men). These
participants answered two questionnaires; one sent by post
before screening and the other presented at screening. A range
of health topics was covered.12 Of relevance to our study were
questions about cardiovascular disease, diabetes mellitus, and
smoking habits. For our analysis we define smoking as daily con-
sumption of cigarettes, cigars, or a pipe.
In the Nord-Tröndelag health study, blood pressure was
measured in seated participants by specially trained staff using a
Dinamap 845XT based on oscillometry.12 In our analysis we
record blood pressure as the mean values of the second and
third of three measurements carried out consecutively at the
same visit. Blood sampling was carried out whenever the partici-
pants attended—that is, in the non-fasting state. Fresh serum was
analysed on a Hitachi 91 autoanalyser. Total cholesterol and high
density lipoprotein cholesterol were measured by an enzymatic
colorimetric cholesterolesterase method.12 Height was measured
to the nearest 1.0 cm and weight to the nearest 0.5 kg. Body mass
index was calculated.
Projection of the guidelines to the study population
We established the proportion of participants at high risk of car-
diovascular disease in a stepwise manner, in accordance with the
guidelines. We calculated the age and sex specific proportions
that should be assigned to the high risk category on the basis of
criteria 1 and 2b-c of the priority list (see box). We used the chart
to estimate risk in the remaining participants. As the chart does
not give exact cut-off points for systolic blood pressure and total
cholesterol, we applied the following limits: systolic blood
pressure (mm Hg) ≤ 119, 120-139, 140-159, and 160-179; total
cholesterol (mmol/l) ≤ 3.9, 4.0-4.9, 5.0-5.9, 6.0-6.9, and 7.0-7.9.
Overall, 283 women (10% of the total) and 186 men (6.9%)
were unclassifiable according to the chart owing to missing data,
mostly on smoking habits. We included all participants in the
denominator when we determined the distribution of risk
categories.
We adapted the priority list on the basis of the data from the
Nord-Tröndelag health study. Under criterion 1 we included
only participants with a history of myocardial infarction or
stroke. We did not calculate low density lipoprotein, as
application of the Friedewald formula is unreliable in
non-fasting people. We included participants who reported
receiving treatment for hypertension and all people with diabe-
tes mellitus in the high risk category.
We display graphically the risk distribution for cardiovascular
disease among the Nord-Tröndelag health study population in
two versions; one based on extrapolation to age 60 as
recommended in the guidelines, the other based on the partici-
pants’ age. In doing so we applied the colour system, without dif-
ferentiating between shades of the same colour. Shaded red
indicates people who are defined as at high risk on the basis of
criteria 1 and 2b-c. Unshaded red indicates high risk according
to the chart (criterion 2a). We used SPSS version 12.0 to analyse
frequencies.
Results
Table 1 gives an overview of participants from the Nord-
Tröndelag health study included in the present analysis. The
participation rate varied from 70% to 89%. Table 2 shows the
proportion of people categorised as at high risk on the basis of
noticeably raised levels of single risk factors (see box) and the
distribution of the combined risk categories, according to the
chart of the systematic coronary risk evaluation project.
If all recommendations including extrapolation of risk to 60
years are applied, 22.5% (95% confidence interval 19.3% to
25.7%) of women and 85.9% (83.2% to 88.6%) of men aged 40
are classified as at high risk for fatal cardiovascular disease (fig 1
and table 2). Only 8.5% (6.5% to 10.9%) of women and no men
aged 40 are classified as at low risk. By age 50, the high risk group
includes 39.5% (35.9% to 43.1%) of women and 88.7% (86.3% to
91.0%) of men and by age 65, 84.0% (80.6% to 87.4%) of women
and 91.6% (88.6% to 94.1%) of men.
The European guidelines’ clinical priority list
The clinical priority list in the European guidelines on cardiovascular
disease prevention in clinical practice (pocket version). Individuals
who fulfill criteria 1 or 2, or both are defined as at high risk
Priorities of cardiovascular disease prevention in clinical practice
1) Patients with established coronary heart disease, peripheral artery
    disease and cerebrovascular atherosclerotic disease
2) Asymptomatic individuals who are at high risk of developing
    atherosclerotic cardiovascular disease because of:
  a) Multiple risk factors resulting in a 10 year risk of ≥5% now (or if
    extrapolated to age 60) for developing a fatal cardiovascular event
  b) Markedly raised levels of single risk factors: cholesterol
    ≥8 mmol/l (320 mg/dl), LDL cholesterol ≥6 mmol/l (240 mg/dl),
    blood pressure ≥180/110 mmHg
  c) Diabetes Type 2 and diabetes Type 1 with microalbuminuria
3) Close relatives (first degree relatives) of:
  a) Patients with early-onset atherosclerotic cardiovascular disease
  b) Asymptomatic individuals at particularly high risk
4) Other individuals met in connection with ordinary clinical practice
Source: De Backer et al 6
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Figure 2 shows the distribution of risk categories without
extrapolation to age 60. Extrapolation explains 86.0% of the
high risk group after evaluation using the chart among women
aged 55. The values for men are 64.4% at age 50 and 18.7% at
age 55.
Discussion
Implementation of the 2003 European guidelines on prevention
of cardiovascular disease in a well defined Norwegian population
would class four out of 10 women and nine out of 10 men aged
Table 1 Participation rates, means, and prevalence of relevant risk factors among participants in Nord-Tröndelag health study 1995-7 (HUNT 2), Norway.
Values are percentages (numbers) unless stated otherwise
Variable
40 years 50 years 55 years 60 years 65 years
Women Men Women Men Women Men Women Men Women Men
No of participants
(participation rate)
657 (80.8) 624 (69.6) 709 (84.1) 698 (76.0) 554 (85.9) 555 (79.9) 471 (88.9) 411 (80.4) 450 (85.1) 419 (81.7)
Mean (SD) systolic
blood pressure
124.0
(14.5)
133.6
(13.1)
133.1
(19.1)
137.5 (16.9) 138.8
(19.8)
140.6 (17.9) 144.6 (21.1) 144.9 (20.6) 150.7
(23.5)
148.4
(20.4)
Mean (SD) diastolic
blood pressure
76.1 (9.8) 80.8 (9.9) 80.8 (11.2) 85.4 (10.9) 82.8 (11.4) 85.4 (10.8) 82.9 (11.6) 87.0 (11.4) 84.5 (13.0) 86.2 (12.1)
Mean (SD) total
cholesterol
concentration
5.4 (1.0) 5.7 (1.1) 6.1 (1.1) 6.1 (1.1) 6.5 (1.2) 6.2 (1.2) 6.8 (1.3) 6.1 (1.1) 6.8 (1.2) 6.2 (1.1)
Mean (SD) body mass
index
25.4 (4.1) 26.3 (3.4) 26.5 (4.4) 27.0 (3.4) 27.1 (4.4) 27.1 (3.5) 27.8 (5.0) 27.1 (3.3) 27.5 (4.7) 27.1 (3.3)
Smokers 46.1
(281/610)
34.8
(204/586)
38.9
(240/617)
34.1
(220/646)
33.7
(157/466)
32.9
(166/505)
32.5
(123/379)
32.7
(118/361)
32.8
(114/348)
33.9
(122/360)
Total cholesterol ≥5
mmol/l
65.7
(430/654)
76.4
(475/622)
86.7
(615/709)
86.2
(600/696)
91.7
(508/554)
88.6
(491/554)
94.1
(443/471)
86.6
(355/410)
95.3
(429/450)
86.9
(364/419)
Blood pressure ≥140/90
mm Hg and
untreated
15.2
(102/657)
36.0
(224/623)
29.8
(211/709)
41.7
(290/696)
37.3
(206/552)
44.8
(248/554)
42.2
(198/469)
52.1
(214/411)
43.8
(196/448)
46.8
(195/417)
Angina without
myocardial infarction
0.2 (1/657) 0.0 (0/624) 1.3 (9/708) 2.1 (15/698) 1.1 (6/549) 2.5 (14/553) 3.8 (18/469) 4.9 (20/411) 4.5
(20/447)
7.5
(31/414)
First degree relatives
with myocardial
infarction before age
60
15.8
(92/581)
20.7
(105/508)
20.6
(132/640)
17.9
(104/582)
21.8
(108/495)
18.5 (86/464) 19.4 (86/444) 17.7 (63/356) 17.8
(76/426)
18.8
(71/377)
Table 2 Percentages (numbers) of women and men at high risk for cardiovascular disease according to criteria 1 and 2b-c in priority list (see box),
distribution of combined risk categories for cardiovascular disease among remaining individuals according to systematic coronary risk evaluation (SCORE)
chart
40 years 50 years 55 years 60 years 65 years
Women Men Women Men Women Men Women Men Women Men
Priority list:
Established myocardial
infarction or stroke
0.3 (2/657) 0.3 (2/624) 1.4
(10/708)
4.3
(30/698)
1.6 (9/549) 8.2
(45/552)
2.6
(12/467)
9.7
(40/411)
5.9 (26/444) 12.8
(53/415)
Systolic blood
pressure ≥180 mm Hg
or diastolic blood
pressure ≥110 mm Hg
0.5 (3/657) 0.5 (3/624) 2.4
(17/709)
2.1
(15/698)
4.7
(26/553)
2.9
(16/554)
7.2
(34/470)
7.3
(30/411)
14.0 (63/449) 6.2
(26/418)
Cholesterol ≥8 mmol/l 1.1 (7/654) 3.5
(22/622)
6.3
(45/709)
5.5
(38/696)
13.0
(72/554)
5.6
(31/554)
17.8
(84/471)
5.4
(22/410)
16.2 (73/450) 6.2
(26/419)
Diabetes 0.3 (2/657) 1.3 (8/616) 2.3
(16/708)
1.6
(11/696)
2.4
(13/551)
3.8
(21/552)
2.8
(13/468)
4.6
(19/410)
3.8 (17/446) 4.6
(19/415)
Receiving treatment
for hypertension
1.8
(12/655)
1.8
(11/621)
8.1
(57/708)
9.3
(65/696)
14.3
(79/551)
14.4
(80/554)
16.8
(79/469)
17.3
(71/411)
28.3
(127/448)
26.9
(112/417)
Sum high risk* 3.8
(25/657)
7.2
(45/624)
17.8
(126/709)
19.5
(136/698)
29.2
(162/554)
26.7
(148/555)
36.7
(173/471)
33.8
(139/411)
51.1
(230/450)
43.4
(182/419)
SCORE chart for
combined risk among
remaining individuals
with extrapolation†:
Unclassifiable‡ 7.0 (46) 6.4 (40) 10.7 (76) 6.6 (46) 11.7 (65) 5.8 (32) 11.9 (56) 8.0 (33) 8.9 (40) 8.4 (35)
High risk 18.7 (123) 78.7 (491) 21.7 (154) 69.2 (483) 19.3 (107) 64.7 (359) 20.6 (97) 55.7 (229) 32.9 (148) 48.2 (202)
Intermediate risk 61.9 (407) 7.7 (48) 46.5 (330) 4.7 (33) 38.6 (214) 2.9 (16) 30.6 (144) 2.4 (10) 7.1 (32) 0 (0)
Low risk 8.5 (56) 0 (0) 3.2 (23) 0 (0) 1.1 (6) 0 (0) 0.2 (1) 0 (0) 0 (0) 0 (0)
Total sum of high risk
group, according to
priority list and
SCORE chart
22.5
(148/657)
85.9
(536/624)
39.5
(280/709)
88.7
(619/698)
48.6
(269/554)
91.4
(507/555)
57.3
(270/471)
89.5
(368/411)
84.0
(378/450)
91.6
(384/419)
*One or more of following criteria present: myocardial infarction, stroke, antihypertensive treatment, diabetes, cholesterol ≥8 mmol/l, systolic blood pressure ≥180 mm Hg, diastolic blood
pressure ≥110 mm Hg.
†Extrapolation to 60 years for ages 40, 50, and 55 (denominator is number of individuals in each cohort).
‡Mostly explained by missing data on smoking habits.
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50 as at high risk for fatal disease. No men aged 40 or older
would be classified as at low risk.
Strengths and limitations of the study
The population of the Nord-Tröndelag health study 1995-7
(HUNT 2) is well defined, considered fairly representative of
Norway, a country which contributed substantial amounts of data
to the systematic coronary risk evaluation project.5 Compared
with other European high risk regions included in the systematic
coronary risk evaluation project or the monitoring trends and
determinants in cardiovascular disease (MONICA) project (third
phase, 1992-4),10 the population did not differ significantly for
cholesterol levels and smoking habits. Blood pressure levels were
higher in the Nord-Tröndelag population than in most
comparable countries, but lower than in Finland.
The adjustments we made to adapt the data from the Nord-
Tröndelag health study to the priority list of the European
guidelines, should not significantly affect our main results.
People with self reported angina, peripheral artery disease, and
high levels of low density lipoprotein cholesterol were not auto-
matically assigned to the high risk group. This contributes to a
conservative estimate of the group before evaluation using the
chart. Patients with diabetes type 1 without microalbuminuria,
however, were included, as were patients receiving treatment for
hypertension, irrespective of blood pressure levels. However, all
patients with diabetes type 1 and people receiving antihyperten-
sive treatment require a level of attention similar to that of peo-
ple recently diagnosed as at high risk. We have no specific
information on the use of lipid lowering drugs among the
participants of the Nord-Tröndelag health study. To the extent
that our population may have included patients receiving such
treatment, this would contribute to a conservative estimate of the
high risk population.
Applicability of 2003 European guidelines
Our findings can be discussed with regard to three explicit
objectives of the guidelines—that is, the development of a risk
estimation system intended for adaptation at national or even
local level; a tool for prioritising patients; and an aid to individual
risk communication and counselling.
Adaptation at national level
A paramount aim of the systematic coronary risk evaluation
project was to encourage development of national guidelines on
prevention of cardiovascular disease.5 6 Applying the Framing-
ham risk equation to European countries overestimated the risk
of cardiovascular disease.4 5 This highlights the importance of
evaluating risk scoring systems against epidemiological data
from the population to be screened before implementation in
clinical practice.13 In addition, a country can show regional
differences in morbidity and mortality.4 A dichotomisation of
Europe into high risk and low risk regions may maintain the ear-
lier introduced imprecision of the risk assessment. Whether the
high risk chart applies to Norway has yet to be investigated.
Tool for prioritising patients
The 2003 European guidelines seem to be intended as a tool to
define the priorities to be set, given limited resources. We found
that the guidelines are unlikely to serve as an effective tool for
prioritising Norwegians, as they classify an unreasonable
number of people as at high risk. Extrapolation of risk to 60
years contributes strongly to this and implies that no men aged
40 or older and only a few women can be considered as at low
risk for cardiovascular disease. Absence of extrapolation,
however, makes it theoretically impossible for someone aged 40
to be classified as at high risk on the basis of the systematic coro-
nary risk evaluation chart. So whereas extrapolation of risk leads
to an overwhelmingly large high risk group, lack of extrapolation
may lead to down prioritising of younger people who might
benefit from early intervention.
Tool for counselling in clinical practice
The vision of the Third Joint Task Force was to make the guide-
lines (or adapted ones) part of standard daily clinical practice
throughout Europe.6 The European Society of Cardiology
encourages visitors to its website (www.escardio.org) to include
these guidelines in their handheld digital systems. The guidelines
are therefore clearly recommended for direct use in counselling
in clinical practice. Several ethical dilemmas may be linked to
implementation of the guidelines in clinical practice. These arise
from the likelihood of overestimating someone’s true risk for
cardiovascular disease. People who contributed data to the
systematic coronary risk evaluation project were mostly recruited
in the 1970s and 80s (Norway, 1974-8). Since the beginning of
the 1970s, mortality from cardiovascular disease has decreased
by 30%-50% in western Europe.1 Lifestyle and body composition
in the Norwegian population has also undergone important
changes.14 A given combination of the relevant risk factors for
cardiovascular disease is likely to predict a lower mortality risk
today than 25 years ago. The systematic coronary risk evaluation
project5 does not discuss the problem of retrospective risk
bias.4 13 A Norwegian group on cardiovascular disease has
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suggested that a 5% risk for mortality in 1985 may correspond to
a 2.5% risk in 2003.15 We question whether it was scientifically
justifiable to include the risk charts of the systematic coronary
risk evaluation project5 in guidelines intended for implementa-
tion in a clinical setting6 before validation in a contemporary
context.
Any overestimation of a person’s risk for cardiovascular
disease can have important implications. Apart from causing
unnecessary concern, it undermines the patient’s informed
choice for intervention. It is also likely to increase prescribing
costs and affect life insurance premiums.4 16 As yet little scientific
knowledge is available on how the communication of this kind of
risk affects people’s understanding of themselves, their bodies,
and their lives.11 17 18
Process for development of guidelines
When guidelines class most adults in one of the world’s longest
living and healthiest populations19 as at high risk and therefore in
need of maximal clinical attention and follow-up, it raises several
scientific and ethical questions.20 The finding predicts major
dilemmas related to workload and resource allocation,21 even in
Norway where the political, economic, social, and medical
circumstances6 reflect excellent access to health care by interna-
tional comparison,19 and the per capita expenditure on health is
among the highest in the world.19 It may be time to reconsider
the aims and means of prevention of cardiovascular disease and
the process of developing guidelines.22
Methods for the development of guidelines for prevention of
disease should be scientifically consistent so as to ensure that
concordance with guidelines is practically feasible and likely to
result in the desired outcomes.23 Evidence from biomedical
research has limited meaning in isolation; it must be regarded in
light of the overall vision, values, strategies, and resources that
exist in the area of preventive medicine, both nationally and
internationally.22–24 Despite the contribution of numerous experts
and professional societies, it seems that authoritative clinical
guidelines on the basis of the systematic coronary risk evaluation
project may be an example of premature application of medical
technology in routine clinical practice.
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What is already known on this topic
Clinicians are urged to implement clinical guidelines in
everyday practice
Clinicians show limited adherence to medical guidelines
that target asymptomatic conditions
What this study adds
Implementation of European guidelines to prevent
cardiovascular disease would label most people in an
unselected Norwegian population at high risk of fatal
disease from age 40
The validity of the evidence base of the guidelines is
questionable and predicts practical and ethical dilemmas
related to resource allocation and clinical counselling
The size of the population at risk should be estimated
before clinical guidelines are issued
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